Orthogon Therapeutics Secures Additional $11M to Advance BK Virus Antiviral Drug Program
Orthogon Therapeutics has announced the successful close of an additional $11 million in follow-on financing, bringing the company’s total capital raised to $36 million. The new funding will be used to accelerate development of its lead therapeutic candidate targeting BK polyomavirus, a pathogen that poses a serious and often under-addressed risk in transplant recipients.
Addressing a Critical Unmet Need in Transplant Medicine
BK polyomavirus infection remains a significant clinical challenge, particularly among patients who have undergone kidney or other solid organ transplants. In these individuals, immunosuppressive therapies—essential for preventing organ rejection—can also weaken the body’s ability to control viral infections. As a result, BK virus can reactivate, leading to complications such as nephropathy, graft dysfunction, and, in severe cases, graft loss.
Despite the seriousness of these complications, there are currently no approved antiviral therapies specifically indicated for BK virus infection. Treatment strategies are largely limited to reducing immunosuppression, which itself carries risks. Orthogon Therapeutics is aiming to change this paradigm by developing a targeted, oral antiviral therapy capable of addressing the full spectrum of BK infection—from early viral reactivation to advanced systemic disease.
A First-in-Class Approach to Viral Targeting
At the center of Orthogon’s pipeline is a novel small-molecule drug designed to inhibit the BK virus by targeting its capsid protein, known as VP1. This represents a significant scientific advancement, as viral capsid proteins have historically been difficult to target with small molecules due to their structural complexity and perceived inaccessibility.
Orthogon’s approach challenges that assumption. By developing compounds that can bind to VP1 and disrupt its function, the company aims to directly interfere with viral replication at its source. This intracellular mechanism of action enables the therapy to exert sustained antiviral effects, even in the presence of viral diversity.
Importantly, the drug candidate has demonstrated activity across multiple BK virus variants, as well as related human polyomaviruses. This broad-spectrum potential is particularly valuable in transplant populations, where viral persistence and mutation can complicate treatment.
Designed for Real-World Clinical Constraints
According to Ali H. Munawar, Ph.D., Chief Executive Officer of Orthogon Therapeutics, the company’s development strategy has been shaped by the unique challenges faced by transplant patients.
“These patients exist within a delicate clinical balance,” Munawar explained. “They require immunosuppressive therapy to maintain organ function, yet this very treatment increases their vulnerability to infections. Additionally, many are already managing a high pill burden. Our goal was to design a therapy that fits seamlessly into this complex care environment.”
As a result, Orthogon’s lead candidate is being developed as an oral therapy, offering a convenient and patient-friendly option that could be integrated into existing treatment regimens without adding significant complexity.
Overcoming Limitations of Antibody-Based Therapies
In parallel with its drug development efforts, Orthogon has conducted extensive research into the biology and genetic diversity of BK virus. The company recently published findings based on the analysis of hundreds of patient-derived viral sequences, shedding light on why existing therapeutic approaches—particularly antibody-based strategies—have shown limited success.
The research revealed that BK virus exhibits significant pre-existing diversity in regions targeted by neutralizing antibodies. Furthermore, the virus is capable of replicating within cellular compartments that are not easily accessible to circulating antibodies. These factors help explain why antibody therapies have struggled to achieve meaningful clinical outcomes.
Orthogon’s small-molecule approach is specifically designed to overcome these limitations by acting داخل the infected cells, directly targeting viral proteins involved in replication. This intracellular activity allows the therapy to bypass the barriers that have hindered other modalities.
Expanding a Novel Antiviral Platform
Beyond its lead VP1-targeting candidate, Orthogon Therapeutics has built a broader platform of small-molecule antivirals that also target the large T antigen (LTAg), another essential protein in the BK virus lifecycle. LTAg plays a critical role in viral replication and host cell interaction, making it an attractive complementary target.
The ability to develop compounds against both VP1 and LTAg represents a significant achievement, as these viral proteins have long been considered difficult to drug. By successfully targeting them, Orthogon is opening new avenues for antiviral drug discovery not only for BK virus but potentially for other related pathogens as well.
Momentum and Industry Engagement
The company’s progress has begun to attract attention within the scientific and medical communities. Orthogon plans to present additional data from its program at major transplant and virology conferences throughout 2026, building on earlier findings shared at American Society of Nephrology Kidney Week 2025.
These presentations are expected to provide further insight into the efficacy and mechanism of action of the company’s lead candidate, as well as its broader antiviral platform.
Broader Applications in Transplant-Associated Infections
While BK virus remains the primary focus, Orthogon Therapeutics is also exploring opportunities to apply its technology to other transplant-associated infections. Patients undergoing transplantation are at increased risk for a range of viral and opportunistic infections, many of which lack effective treatments.
By leveraging its expertise in targeting difficult viral proteins with small molecules, the company aims to expand its pipeline into additional areas of unmet medical need. This strategy not only diversifies its portfolio but also positions Orthogon as a potential leader in the development of next-generation antivirals for immunocompromised populations.
With the completion of its latest financing round, Orthogon Therapeutics is well-positioned to advance its innovative approach to treating BK polyomavirus infection. By targeting viral proteins previously considered undruggable and designing therapies tailored to the realities of transplant care, the company is addressing a critical gap in current medical practice.
As development progresses, Orthogon’s work has the potential to significantly improve outcomes for transplant patients, offering a much-needed therapeutic option where none currently exists. The combination of scientific innovation, clinical insight, and strategic investment underscores the company’s commitment to transforming the treatment landscape for BK virus and beyond.
About BK and polyomaviruses:
BK virus (BKV) is among the most widespread chronic viral infections in humans. A member of the polyomavirus family, BKV establishes a lifelong infection in 80–90% of healthy adults worldwide. Reactivation occurs in the kidneys of nearly half of all solid organ and stem cell transplant recipients, leading to severe complications and graft loss. Other human polyomaviruses, including JC virus and Merkel cell polyomavirus, cause fatal progressive multifocal leukoencephalopathy (PML) and aggressive Merkel cell carcinoma, respectively.
About Orthogon Therapeutics:
Orthogon is a polyomavirus-focused biotech built on a proprietary discovery platform that fuses structure-based drug design with deep biophysical interrogation of viral proteins, unlocking targets long considered undruggable. The company is headquartered in Greater Boston with a research branch in Leuven, Belgium. To learn more visit www.orthogontherapeutics.com
Source Link:https://www.businesswire.com/
